These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34359653)

  • 1. A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor-Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy.
    Gong C; Ruiz-Martinez A; Kimko H; Popel AS
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model.
    Ruiz-Martinez A; Gong C; Wang H; Sové RJ; Mi H; Kimko H; Popel AS
    PLoS Comput Biol; 2022 Jul; 18(7):e1010254. PubMed ID: 35867773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response.
    Zhang S; Gong C; Ruiz-Martinez A; Wang H; Davis-Marcisak E; Deshpande A; Popel AS; Fertig EJ
    Immunoinformatics (Amst); 2021 Oct; 1-2():. PubMed ID: 34708216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications.
    Sové RJ; Jafarnejad M; Zhao C; Wang H; Ma H; Popel AS
    CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):484-497. PubMed ID: 32618119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Informing virtual clinical trials of hepatocellular carcinoma with spatial multi-omics analysis of a human neoadjuvant immunotherapy clinical trial.
    Zhang S; Deshpande A; Verma BK; Wang H; Mi H; Yuan L; Ho WJ; Jaffee EM; Zhu Q; Anders RA; Yarchoan M; Kagohara LT; Fertig EJ; Popel AS
    bioRxiv; 2023 Aug; ():. PubMed ID: 37645761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying Intratumoral Heterogeneity and Immunoarchitecture Generated In-Silico by a Spatial Quantitative Systems Pharmacology Model.
    Nikfar M; Mi H; Gong C; Kimko H; Popel AS
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment.
    Norton KA; Gong C; Jamalian S; Popel AS
    Processes (Basel); 2019 Jan; 7(1):. PubMed ID: 30701168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer.
    Cook D; Biancalana M; Liadis N; Lopez Ramos D; Zhang Y; Patel S; Peterson JR; Pfeiffer JR; Cole JA; Antony AK
    Front Artif Intell; 2023; 6():1153083. PubMed ID: 37138891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy.
    Lemaire V; Bassen D; Reed M; Song R; Khalili S; Lien YTK; Huang L; Singh AP; Stamatelos S; Bottino D; Hua F
    Clin Pharmacol Ther; 2023 May; 113(5):963-972. PubMed ID: 36282521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
    Wang H; Ma H; Sové RJ; Emens LA; Popel AS
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.
    Chelliah V; Lazarou G; Bhatnagar S; Gibbs JP; Nijsen M; Ray A; Stoll B; Thompson RA; Gulati A; Soukharev S; Yamada A; Weddell J; Sayama H; Oishi M; Wittemer-Rump S; Patel C; Niederalt C; Burghaus R; Scheerans C; Lippert J; Kabilan S; Kareva I; Belousova N; Rolfe A; Zutshi A; Chenel M; Venezia F; Fouliard S; Oberwittler H; Scholer-Dahirel A; Lelievre H; Bottino D; Collins SC; Nguyen HQ; Wang H; Yoneyama T; Zhu AZX; van der Graaf PH; Kierzek AM
    Clin Pharmacol Ther; 2021 Mar; 109(3):605-618. PubMed ID: 32686076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emulation of Quantitative Systems Pharmacology models to accelerate virtual population inference in immuno-oncology.
    Pawłowski T; Bokota G; Lazarou G; Kierzek AM; Sroka J
    Methods; 2024 Mar; 223():118-126. PubMed ID: 38246229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition.
    Wang H; Arulraj T; Kimko H; Popel AS
    NPJ Precis Oncol; 2023 Jun; 7(1):55. PubMed ID: 37291190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition.
    Wang H; Arulraj T; Kimko H; Popel AS
    bioRxiv; 2023 Apr; ():. PubMed ID: 37162938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.
    Jafarnejad M; Gong C; Gabrielson E; Bartelink IH; Vicini P; Wang B; Narwal R; Roskos L; Popel AS
    AAPS J; 2019 Jun; 21(5):79. PubMed ID: 31236847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging multi-omics data to empower quantitative systems pharmacology in immuno-oncology.
    Arulraj T; Wang H; Ippolito A; Zhang S; Fertig EJ; Popel AS
    Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38557676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager.
    Anbari S; Wang H; Zhang Y; Wang J; Pilvankar M; Nickaeen M; Hansel S; Popel AS
    Front Pharmacol; 2023; 14():1163432. PubMed ID: 37408756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.
    Kosinsky Y; Dovedi SJ; Peskov K; Voronova V; Chu L; Tomkinson H; Al-Huniti N; Stanski DR; Helmlinger G
    J Immunother Cancer; 2018 Feb; 6(1):17. PubMed ID: 29486799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework.
    Leete JC; Zager MG; Musante CJ; Shtylla B; Qiao W
    Front Pharmacol; 2022; 13():1056365. PubMed ID: 36545310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer.
    Wang H; Zhao C; Santa-Maria CA; Emens LA; Popel AS
    iScience; 2022 Aug; 25(8):104702. PubMed ID: 35856032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.